Plant Name: Dahlstedtia pentaphylla
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; FFAR1; FFAR4; GPBAR1; | |
| PTPN1; DUSP3; PTPN2; ACP1; PTPRF; | |
| RECQL; TDP1; BLM; AKR1B10; HPGD; AKR1B1; HSD17B10; ALOX15; HSD11B1; USP2; APEX1; POLB; | |
| GAA; | |
| FLT4; TEK; PDGFRB; GSK3B; AKT1; MET; PLK4; BRAF; ERBB2; EGFR; AURKB; NUAK1; EPHB4; AURKA; PLK1; INSR; SRC; IGF1R; MAP3K8; KDR; PTK2; CSNK2A1; | |
| CA2; CA12; CA1; CA13; CA9; CA14; CA5A; CA3; CA7; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| RORC; | |
| NR1H4; | |
| KDM4E; | |
| BACE1; | |
| SLC22A6; | |
| SMAD3; LMNA; FABP3; MAPT; HBB; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.547E-11 | 6.707E-09 | AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, EGFR, EPHB4, ERBB2, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, NUAK1, PDGFRB, PLK1, PLK4, PTK2, RECQL, SRC, TEK |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.254E-10 | 1.016E-07 | BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, NR1H4, PPARA, PPARD, PPARG, PTPN1, RORC, SMAD3 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 7.626E-09 | 1.496E-06 | FFAR4, NR1H4, PPARA, PPARD, PPARG, PTPN2, SMAD3, TEK |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.072E-08 | 1.955E-06 | ALOX15, EGFR, ERBB2, PDGFRB, PPARA, PPARD, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.592E-08 | 2.751E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.853E-08 | 3.153E-06 | EGFR, ERBB2, INSR, KDR |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 2.007E-08 | 3.388E-06 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.323E-08 | 5.282E-06 | ALOX15, BRAF, EGFR, FFAR4, FLT4, KDR, PDGFRB, SRC, TEK |
| MF | Unclassified; | GO:0004872; receptor activity | 5.746E-08 | 8.454E-06 | EGFR, EPHB4, ERBB2, FFAR1, FFAR4, FLT4, GPBAR1, GPR35, HPGD, IGF1R, INSR, KDR, MET, NR1H4, PDGFRB, PPARA, PPARD, PPARG, PTPRF, RORC, TEK |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.807E-08 | 9.816E-06 | EGFR, ERBB2, INSR, MET, PDGFRB, PTK2, SRC, TEK |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 1.122E-07 | 1.462E-05 | AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, PDGFRB, PLK1, PTK2, PTPN1, PTPN2, SMAD3, SRC |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.220E-07 | 3.810E-05 | CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 3.404E-07 | 3.943E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 8.473E-07 | 8.622E-05 | NR1H4, PPARA, PPARD, PPARG, RORC |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.389E-06 | 1.304E-04 | EGFR, EPHB4, ERBB2, FFAR1, FFAR4, FLT4, GPBAR1, GPR35, HPGD, IGF1R, INSR, KDR, MET, PDGFRB, PPARG, PTPRF, TEK |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.164E-06 | 1.963E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 3.789E-06 | 3.186E-04 | KDR, PDGFRB, PPARD, PTK2, TEK |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 3.809E-06 | 3.190E-04 | PDGFRB, PTK2, SRC, TEK |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 4.972E-06 | 4.070E-04 | EPHB4, GAA, INSR, PTK2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 7.010E-06 | 5.591E-04 | NR1H4, PPARA, PPARD, PPARG, RORC, SRC |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 7.620E-06 | 5.968E-04 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
| BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 9.009E-06 | 6.932E-04 | AKT1, CA2, PDGFRB, SRC |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1.042E-05 | 7.772E-04 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.139E-05 | 8.377E-04 | AKT1, BLM, BRAF, CSNK2A1, EGFR, ERBB2, FLT4, HPGD, IGF1R, KDR, MAPT, MET, PLK1, PLK4, PPARG, SLC22A6, SMAD3, USP2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.258E-05 | 9.083E-04 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.495E-05 | 1.047E-03 | AKR1B1, AKR1B10, AKT1, ALOX15, APEX1, GAA, GSK3B, HPGD, HSD11B1, HSD17B10, KDM4E, PPARD, PPARG |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.702E-05 | 1.177E-03 | ACP1, AKR1B1, AKR1B10, AKT1, ALOX15, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CSNK2A1, DUSP3, EPHB4, ERBB2, FABP3, GSK3B, HBB, HPGD, HSPA1A, LMNA, MAP3K8, MAPT, PLK1, PLK4, PPARG, PTK2, PTPN1, PTPN2, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 1.925E-05 | 1.306E-03 | FLT4, KDR, PDGFRB |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 2.211E-05 | 1.469E-03 | AKT1, FFAR1, INSR, NR1H4, PPARG, PTPN2 |
| MF | Unclassified; | GO:0032403; protein complex binding | 2.212E-05 | 1.469E-03 | APEX1, EGFR, IGF1R, INSR, KDR, PLK1, PPARA, PTPN1, PTPN2, PTPRF, SMAD3, SRC |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.589E-05 | 1.678E-03 | AKT1, BRAF, CA2, EGFR, ERBB2, GSK3B, INSR, KDR, MAPT, NR1H4, PDGFRB, PPARD, PPARG, PTK2, PTPN2, PTPRF, SMAD3, SRC, TEK |
| BP | Unclassified; | GO:0006461; protein complex assembly | 2.636E-05 | 1.698E-03 | BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, MAPT, PTK2, SLC22A6, SMAD3, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 2.769E-05 | 1.773E-03 | ACP1, DUSP3, PTPN1, PTPN2, PTPRF |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 3.085E-05 | 1.941E-03 | AKR1B1, AKT1, APEX1, AURKA, AURKB, BLM, CSNK2A1, DUSP3, GSK3B, HPGD, HSPA1A, LMNA, NR1H4, NUAK1, PLK1, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, RORC, SMAD3, SRC, USP2 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 3.213E-05 | 2.001E-03 | AKT1, AURKA, BRAF, CA2, INSR, KDR, LMNA, MAPT, NR1H4, PDGFRB, PPARD, PPARG, SMAD3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.764E-05 | 2.277E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.764E-05 | 2.277E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.764E-05 | 2.277E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.792E-05 | 2.281E-03 | NR1H4, PPARA, PPARD, PPARG, RORC, SRC |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 3.826E-05 | 2.283E-03 | AURKA, AURKB, PLK1, POLB |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 3.915E-05 | 2.329E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1 |
| BP | GO:0050896; response to stimulus | GO:0042542; response to hydrogen peroxide | 4.209E-05 | 2.476E-03 | AKR1B1, APEX1, HBB, PDGFRB, SRC |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 4.209E-05 | 2.476E-03 | AKR1B1, AKT1, APEX1, EGFR, SRC |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.541E-05 | 3.183E-03 | PDGFRB, POLB, PPARG |
| BP | GO:0009987; cellular process | GO:0051259; protein oligomerization | 6.414E-05 | 3.618E-03 | BLM, BRAF, HBB, HSD17B10, IGF1R, INSR, MAPT, SLC22A6, TEK |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 6.535E-05 | 3.677E-03 | AKR1B1, APEX1, BLM, BRAF, EGFR, KDR, SRC |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 6.691E-05 | 3.745E-03 | AKR1B1, AKR1B10, HPGD, HSD11B1, HSD17B10 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 7.511E-05 | 4.109E-03 | PTPN1, PTPN2 |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 8.061E-05 | 4.366E-03 | AKT1, KDR, MAPT, SRC |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 8.305E-05 | 4.488E-03 | BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 9.094E-05 | 4.824E-03 | EGFR, ERBB2, MET, PDGFRB |
| BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 9.376E-05 | 4.943E-03 | AKT1, CSNK2A1, MAPT, PPARG, SMAD3, SRC |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 9.486E-05 | 4.989E-03 | AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, PPARG, SRC, USP2 |
| BP | GO:0040011; locomotion | GO:0014910; regulation of smooth muscle cell migration | 9.646E-05 | 5.025E-03 | APEX1, PDGFRB, PPARD, SRC |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 9.646E-05 | 5.025E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 1.017E-04 | 5.262E-03 | AKT1, EGFR, PLK1, SMAD3, SRC |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.249E-04 | 6.113E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.249E-04 | 6.113E-03 | BLM, RECQL |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.249E-04 | 6.113E-03 | AURKA, AURKB |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.277E-04 | 6.159E-03 | FLT4, KDR, PTK2, SRC |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.341E-04 | 6.401E-03 | AKT1, MAPT, PTPN1 |
| MF | GO:0005488; binding | GO:0051059; NF-kappaB binding | 1.341E-04 | 6.401E-03 | APEX1, GSK3B, PPARD |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 1.348E-04 | 6.422E-03 | CA2, PDGFRB, PPARG, TEK |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.491E-04 | 6.969E-03 | IGF1R, INSR, PDGFRB |
| CC | GO:0043226; organelle | GO:0051233; spindle midzone | 1.825E-04 | 8.145E-03 | AURKA, AURKB, PLK1 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 1.869E-04 | 8.156E-03 | PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0060336; negative regulation of interferon-gamma-mediated signaling pathway | 1.869E-04 | 8.156E-03 | PPARG, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 1.869E-04 | 8.156E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.869E-04 | 8.156E-03 | ALOX15, HPGD |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 1.869E-04 | 8.156E-03 | AURKA, AURKB |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 1.869E-04 | 8.156E-03 | FABP3, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.869E-04 | 8.156E-03 | CA1, CA2 |
| CC | GO:0044464; cell part | GO:0097443; sorting endosome | 1.869E-04 | 8.156E-03 | KDR, PTPN1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.009E-04 | 8.714E-03 | CSNK2A1, KDR, MAPT |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.057E-25 | 1.537E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.035E-20 | 3.305E-16 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.044E-17 | 1.723E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.341E-24 | 6.642E-22 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.260E-15 | 9.636E-14 | PTPN1; SMAD3; CSNK2A1; SRC; INSR; ERBB2; ACP1; MET; PTPRF; EGFR; IGF1R |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 4.322E-12 | 2.204E-10 | PDGFRB; GSK3B; SRC; FLT4; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.482E-10 | 5.669E-09 | PDGFRB; SRC; INSR; FLT4; KDR; AKT1; BRAF; TEK; MET; EGFR; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.008E-08 | 3.086E-07 | PDGFRB; GSK3B; SMAD3; ERBB2; AKT1; BRAF; PPARG; MET; EGFR; PTK2; PPARD; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.275E-08 | 3.986E-07 | PDGFRB; GSK3B; INSR; FLT4; KDR; AKT1; TEK; MET; PTK2; EGFR; IGF1R |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.206E-08 | 4.905E-07 | SRC; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.345E-08 | 3.986E-07 | PDGFRB; GSK3B; ERBB2; AKT1; BRAF; EGFR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.999E-08 | 3.986E-07 | GSK3B; SRC; ERBB2; AKT1; BRAF; EGFR; PTK2 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.840E-08 | 3.986E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; BRAF; EGFR; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 8.371E-08 | 1.164E-06 | PDGFRB; INSR; FLT4; KDR; AKT1; TEK; MET; EGFR; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.621E-07 | 2.067E-06 | PDGFRB; AKT1; BRAF; MET; EGFR; IGF1R |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.674E-06 | 2.557E-05 | PDGFRB; DUSP3; AKT1; BRAF; MAP3K8; MAPT; EGFR; HSPA1A |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.667E-07 | 1.138E-05 | GSK3B; ERBB2; AKT1; BRAF; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.485E-06 | 1.623E-05 | INSR; ERBB2; AKT1; TEK; EGFR; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.069E-06 | 2.110E-05 | PTPN1; GSK3B; INSR; AKT1; PPARA; PTPRF |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.968E-06 | 2.671E-05 | PDGFRB; AKT1; BRAF; EGFR; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.202E-06 | 2.722E-05 | SMAD3; ERBB2; AKT1; BRAF; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.451E-06 | 2.779E-05 | PDGFRB; ERBB2; AKT1; MET; EGFR |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 8.461E-06 | 6.472E-05 | PTPN1; GSK3B; INSR; AKT1; BRAF; PTPRF |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 3.065E-05 | 2.132E-04 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.162E-05 | 2.769E-04 | ERBB2; AKT1; BRAF; EGFR |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.837E-05 | 3.721E-04 | SRC; KDR; AKT1; PTK2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 9.635E-05 | 5.265E-04 | GSK3B; AKT1; BRAF; PPARA; EGFR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 6.224E-05 | 3.809E-04 | GSK3B; SMAD3; AKT1; BRAF |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 7.052E-05 | 4.150E-04 | INSR; AKT1; HSPA1A; IGF1R |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.193E-05 | 8.693E-05 | SRC; ERBB2; BRAF; EGFR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.132E-04 | 1.597E-03 | INSR; AKT1; PPARG; IGF1R |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 3.671E-04 | 1.812E-03 | PLK1; AKT1; BRAF; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.816E-04 | 1.824E-03 | SRC; AKT1; EGFR; HSPA1A |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.690E-04 | 2.110E-03 | GSK3B; SRC; AKT1; BRAF; PTK2 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 9.471E-05 | 5.265E-04 | FABP3; PPARG; PPARA; PPARD |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.940E-04 | 1.827E-03 | HPGD; PPARG; MET; PTK2; IGF1R |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 8.628E-04 | 3.772E-03 | PDGFRB; SRC; BRAF; PTK2; EGFR |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 8.915E-04 | 3.789E-03 | INSR; AKT1; PPARG; IGF1R |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.256E-03 | 4.928E-03 | GSK3B; CSNK2A1; AKT1; HSPA1A |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 9.745E-04 | 4.030E-03 | GSK3B; MET; PTK2; EPHB4 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.473E-03 | 5.496E-03 | GSK3B; SMAD3; CSNK2A1; PPARD |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.473E-03 | 5.496E-03 | GSK3B; SMAD3; AKT1; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.550E-03 | 5.516E-03 | PDGFRB; INSR; AKT1; EGFR |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.845E-03 | 6.272E-03 | GSK3B; INSR; AKT1; PPARA |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.972E-03 | 6.436E-03 | PDGFRB; POLB; GSK3B; SMAD3; AKT1 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.215E-03 | 6.917E-03 | PDGFRB; FLT4; KDR; MET; EGFR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.006E-03 | 4.052E-03 | AKT1; BRAF; PPARD |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.717E-03 | 8.150E-03 | BACE1; GSK3B; MAPT; HSD17B10 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 5.235E-03 | 1.430E-02 | GSK3B; CSNK2A1; AKT1; HSPA1A |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.539E-03 | 5.516E-03 | AKT1; BRAF; MET |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.977E-03 | 6.436E-03 | GSK3B; SRC; AKT1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.057E-03 | 6.556E-03 | SMAD3; AKT1; BRAF |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.678E-03 | 5.834E-03 | SRC; MET; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.145E-03 | 1.430E-02 | PDGFRB; AKT1; EGFR |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 5.581E-03 | 1.472E-02 | GSK3B; AKT1; MAP3K8 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.485E-03 | 7.604E-03 | SRC; MET; PTK2 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.498E-03 | 1.010E-02 | PDGFRB; SRC; EGFR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.277E-03 | 2.043E-02 | GSK3B; AKT1; BRAF |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.905E-03 | 1.983E-02 | GSK3B; SRC; AKT1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 8.854E-03 | 2.150E-02 | PLK1; AURKA; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.406E-02 | 3.163E-02 | SMAD3; SRC; AKT1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.232E-02 | 2.881E-02 | CSNK2A1; SRC; AKT1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.938E-02 | 4.061E-02 | PDGFRB; ERBB2; MET; EGFR |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 9.052E-03 | 2.164E-02 | GSK3B; SMAD3; PLK1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.435E-02 | 4.841E-02 | PDGFRB; ERBB2; EGFR |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.264E-02 | 4.618E-02 | GSK3B; AKT1; HSPA1A |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.493E-04 | 7.874E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.436E-02 | 4.841E-02 | AKT1; PPARA |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.825E-02 | 3.879E-02 | AKT1; BRAF |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.602E-02 | 3.553E-02 | INSR; AKT1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.502E-02 | 4.907E-02 | CA2; NR1H4 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.825E-02 | 3.879E-02 | BRAF; IGF1R |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.122E-02 | 4.387E-02 | SMAD3; RORC |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.768E-02 | 3.865E-02 | AKR1B10; AKR1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.292E-02 | 2.949E-02 | INSR; IGF1R |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 1.243E-02 | 2.881E-02 | HBB; MET |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.484E-03 | 1.271E-02 | BRAF; PPARG |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 5.442E-03 | 1.461E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 6.851E-03 | 1.747E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 5.780E-03 | 1.499E-02 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.832E-03 | 8.333E-03 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; ERBB2; EGFR; EGFR; IGF1R |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; CA9; ERBB2; EGFR; PLK1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; BRAF; AURKA |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1 |
| C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; INSR; MAPT; PPARG; PPARG |
| C00-D49: Neoplasms | AML | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Bladder cancer | C67 | ERBB2; EGFR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR; EGFR; BRAF |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR; ERBB2; EGFR; EGFR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; BRAF |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | BRAF |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; KDR; EGFR; PLK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4; HSD11B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ERBB2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1; PDGFRB; GSK3B; INSR; AKR1B1; PPARG; HSD11B1; HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PDGFRB; MET; KDR; EGFR; EGFR; IGF1R; IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; INSR; HSD11B1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; PPARG; HSD11B1 |
| C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT4; TEK; GSK3B; AKT1; MET; CA1; KDR; SRC; CA9; ERBB2; ERBB2; EGFR; EPHB4; PLK1; IGF1R; PTK2; BRAF; BRAF; AURKA; CSNK2A1 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; ERBB2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT4; TEK; PDGFRB; AKT1; MET; KDR; KDR; KDR; SRC; CA9; ERBB2; EGFR; PLK1; PLK1; IGF1R; PTK2; AURKB; AURKA |
| C00-D49: Neoplasms | Solid tumors | NA | BRAF |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PLK1; AURKA |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| C00-D49: Neoplasms | Breast cancer | C50 | INSR; KDR; KDR; KDR; CA9; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; IGF1R |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR; EGFR; EGFR; EGFR; AKR1B1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | FLT4; MET; KDR; IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | PLK1; AURKB; AURKA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; ERBB2; EGFR; PLK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PPARG |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; INSR; PPARD; GPBAR1; PPARG; PPARG; HSD11B1 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |